outcome of Board meeting held on July 25, 2025
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences' Board approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations rose modestly to Rs. 16,892 lakhs, up about 2% from Rs. 16,542 lakhs in the same quarter last year. Other income more than doubled year-on-year to Rs. 523 lakhs from Rs. 237 lakhs. Profit before tax stood at Rs. 3,543 lakhs (vs Rs. 3,600 lakhs a year ago), while net profit (PAT) was Rs. 2,629 lakhs, marginally lower than Rs. 2,676 lakhs in Q1 FY25. EPS came in at Rs. 15.90 versus Rs. 16.18 previously. The quarter includes a large exceptional gain of Rs. 10,990 lakhs from the assignment of surplus vacant leasehold land at MIDC, Navi Mumbai, and the notes also describe a Rs. 1,633 lakh net loss recognized in Q4 FY25 from a January 2025 fire at one block of the company's API plant in Navi Mumbai, which is under insurance claim. Statutory auditors SRBC & Co LLP issued an unmodified limited review report.
Core operating performance was broadly flat year-on-year, with revenue showing only marginal growth and PAT slightly down, suggesting limited underlying momentum in the pharma business. However, the sizeable one-time land sale gain will boost reported Q1 earnings and strengthen other equity, while the fire-related loss remains a non-recurring drag already provided for last fiscal. The net effect is likely positive for headline earnings, though investors should focus on the ex-exceptional profit trend when assessing the business.